119 related articles for article (PubMed ID: 32169399)
41. The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF-1α and VEGF.
Şalva E; Turan SÖ; Eren F; Akbuğa J
Int J Pharm; 2015 Jan; 478(1):147-154. PubMed ID: 25445537
[TBL] [Abstract][Full Text] [Related]
42. The Antiangiogenic Effects of Gold Nanoparticles on Experimental Choroidal Neovascularization in Mice.
Roh YJ; Rho CR; Cho WK; Kang S
Invest Ophthalmol Vis Sci; 2016 Dec; 57(15):6561-6567. PubMed ID: 27918830
[TBL] [Abstract][Full Text] [Related]
43. Hyaluronic acid reagent functional chitosan-PEI conjugate with AQP2-siRNA suppressed endometriotic lesion formation.
Zhao MD; Cheng JL; Yan JJ; Chen FY; Sheng JZ; Sun DL; Chen J; Miao J; Zhang RJ; Zheng CH; Huang HF
Int J Nanomedicine; 2016; 11():1323-36. PubMed ID: 27099493
[TBL] [Abstract][Full Text] [Related]
44. Silencing fibroblast growth factor 7 inhibits krypton laser-induced choroidal neovascularization in a rat model.
Zhang C; Han M; Wu S
J Cell Biochem; 2019 Aug; 120(8):13792-13801. PubMed ID: 31017714
[TBL] [Abstract][Full Text] [Related]
45. Lactic Acid Upregulates VEGF Expression in Macrophages and Facilitates Choroidal Neovascularization.
Song J; Lee K; Park SW; Chung H; Jung D; Na YR; Quan H; Cho CS; Che JH; Kim JH; Park JH; Seok SH
Invest Ophthalmol Vis Sci; 2018 Jul; 59(8):3747-3754. PubMed ID: 30046816
[TBL] [Abstract][Full Text] [Related]
46. Triptolide-nanoliposome-APRPG, a novel sustained-release drug delivery system targeting vascular endothelial cells, enhances the inhibitory effects of triptolide on laser-induced choroidal neovascularization.
Lai K; Li Y; Gong Y; Li L; Huang C; Xu F; Zhong X; Jin C
Biomed Pharmacother; 2020 Nov; 131():110737. PubMed ID: 32932044
[TBL] [Abstract][Full Text] [Related]
47. Silencing of GFP expression in human mesenchymal stem cells using quaternary polyplexes of siRNA-PEI with glycosaminoglycans and albumin.
Herrera LC; Shastri VP
Acta Biomater; 2019 Nov; 99():397-411. PubMed ID: 31541736
[TBL] [Abstract][Full Text] [Related]
48. Combinatorial siRNA Polyplexes for Receptor Targeting.
Lee DJ; Wagner E
Methods Mol Biol; 2019; 1974():83-98. PubMed ID: 31098997
[TBL] [Abstract][Full Text] [Related]
49. Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles.
Chu Y; Chen N; Yu H; Mu H; He B; Hua H; Wang A; Sun K
Int J Nanomedicine; 2017; 12():1353-1368. PubMed ID: 28260884
[TBL] [Abstract][Full Text] [Related]
50. Laser-induced choroidal neovascularization in mice attenuated by deficiency in the apelin-APJ system.
Hara C; Kasai A; Gomi F; Satooka T; Sakimoto S; Nakai K; Yoshioka Y; Yamamuro A; Maeda S; Nishida K
Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):4321-9. PubMed ID: 23722395
[TBL] [Abstract][Full Text] [Related]
51. Novel biotinylated chitosan-graft-polyethyleneimine copolymer as a targeted non-viral vector for anti-EGF receptor siRNA delivery in cancer cells.
Darvishi MH; Nomani A; Amini M; Shokrgozar MA; Dinarvand R
Int J Pharm; 2013 Nov; 456(2):408-16. PubMed ID: 24012865
[TBL] [Abstract][Full Text] [Related]
52. GABA
Ni S; Liu Y; Tang Y; Chen J; Li S; Pu J; Han L
Carbohydr Polym; 2018 Jan; 179():135-144. PubMed ID: 29111036
[TBL] [Abstract][Full Text] [Related]
53. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2.
Renno RZ; Terada Y; Haddadin MJ; Michaud NA; Gragoudas ES; Miller JW
Arch Ophthalmol; 2004 Jul; 122(7):1002-11. PubMed ID: 15249365
[TBL] [Abstract][Full Text] [Related]
54. Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept.
Hong HK; Park YJ; Kim DK; Ryoo NK; Ko YJ; Park KH; Kim HM; Woo SJ
Invest Ophthalmol Vis Sci; 2020 Nov; 61(13):22. PubMed ID: 33196778
[TBL] [Abstract][Full Text] [Related]
55. Oral Delivery of a Tetrameric Tripeptide Inhibitor of VEGFR1 Suppresses Pathological Choroid Neovascularization.
Tarallo V; Iaccarino E; Cicatiello V; Sanna R; Ruvo M; De Falco S
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936463
[TBL] [Abstract][Full Text] [Related]
56. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo.
Lee SJ; Yook S; Yhee JY; Yoon HY; Kim MG; Ku SH; Kim SH; Park JH; Jeong JH; Kwon IC; Lee S; Lee H; Kim K
J Control Release; 2015 Dec; 220(Pt B):631-41. PubMed ID: 26307351
[TBL] [Abstract][Full Text] [Related]
57. Chitosan-hyaluronic acid nanoparticles for gene silencing: the role of hyaluronic acid on the nanoparticles' formation and activity.
Al-Qadi S; Alatorre-Meda M; Zaghloul EM; Taboada P; Remunán-López C
Colloids Surf B Biointerfaces; 2013 Mar; 103():615-23. PubMed ID: 23274155
[TBL] [Abstract][Full Text] [Related]
58. Polyplexes of retinoic acid: an in vitro study of complex nanostructures against colorectal cancer cell line (HCT-15).
Ture N; Desai D; Shende P
J Mater Sci Mater Med; 2021 Sep; 32(9):122. PubMed ID: 34519890
[TBL] [Abstract][Full Text] [Related]
59. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model.
Reich SJ; Fosnot J; Kuroki A; Tang W; Yang X; Maguire AM; Bennett J; Tolentino MJ
Mol Vis; 2003 May; 9():210-6. PubMed ID: 12789138
[TBL] [Abstract][Full Text] [Related]
60. [Chitosan-siRNA complex nanoparticles for gene silencing].
Liu X
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Feb; 27(1):97-101. PubMed ID: 20337033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
